FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(BatchIngestion)
(‎Changed label, description and/or aliases in pt)
 
(3 intermediate revisions by 2 users not shown)
label / ptlabel / pt
PARA A GENEVAX: DE GENES A VACINAS TRANSNACIONAIS
Para a GENEVAX: DOS GÉNEROS ÀS VACINAS TRANSNACIONAIS
Property / contained in Local Administrative Unit
 
Property / contained in Local Administrative Unit: Roma / rank
Normal rank
 
Property / summary: GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English) / qualifier
 
readability score: 0.0615315350982328
Amount0.0615315350982328
Unit1
Property / summaryProperty / summary
AS VACINAS GENÉTICAS TÊM MÚLTIPLOS BENEFÍCIOS POTENCIAIS, INCLUINDO O DIRECIONAMENTO ESPECÍFICO, O USO DE MÚLTIPLOS GENES PARA MELHORAR A IMUNOLOGIA, A VELOCIDADE DOS RESUMOS E A REDUÇÃO DO RISCO EM RELAÇÃO ÀS VACINAS CONVENCIONAIS. EVVIVAX Ê UMA NOVA EMPRESA CH (Portuguese)
As vacinas genéticas têm múltiplas vantagens potenciais, incluindo uma orientação específica, a utilização de múltiplos genes para melhorar a imunologia, a velocidade dos resumos e a redução do risco em relação às vacinas convencionais. EVVIVAX Ê Uma NOVA EMPRESA CH (Portuguese)
Property / contained in Local Administrative Unit
 
Property / contained in Local Administrative Unit: Roma / rank
 
Normal rank

Latest revision as of 16:23, 7 October 2024

Project Q2035463 in Italy
Language Label Description Also known as
English
FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES
Project Q2035463 in Italy

    Statements

    country
    Italy
    0 references
    EU contribution
    136,610.15 Euro
    0 references
    budget
    308,305.94 Euro
    0 references
    co-financing rate
    44.31 percent
    0 references
    start time
    6 April 2018
    0 references
    end time
    6 November 2020
    0 references
    expected end time
    13 October 2019
    0 references
    beneficiary name (string)
    EVVIVAX S.R.L.
    0 references
    ISTITUTO SUPERIORE DI SANITA'
    0 references
    beneficiary
    Q282303
    0 references
    Q275708
    0 references
    programme
    Lazio - ERDF
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà, LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
    0 references
    GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
    readability score
    0.0615315350982328
    0 references
    LES VACCINS GÉNÉTIQUES PRÉSENTENT DE MULTIPLES AVANTAGES POTENTIELS, Y COMPRIS UN CIBLAGE SPÉCIFIQUE, L’UTILISATION DE GÈNES MULTIPLES POUR AMÉLIORER L’IMMUNITÉ, LA VITESSE DE SYNTHÈSE ET LA RÉDUCTION DES RISQUES PAR RAPPORT AUX VACCINS CONVENTIONNELS. EVVIVAX Ê UNE NOUVELLE ENTREPRISE QUI (French)
    point in time
    16 December 2021
    0 references
    GENETISCHE VACCINS HEBBEN MEERDERE POTENTIËLE VOORDELEN, WAARONDER SPECIFIEKE TARGETING, HET GEBRUIK VAN MEERDERE GENEN OM DE IMMUNITEIT, DE SYNTHESESNELHEID EN DE RISICOVERMINDERING TE VERBETEREN IN VERGELIJKING MET CONVENTIONELE VACCINS. EVVIVAX Ê EEN NIEUW BEDRIJF DAT (Dutch)
    point in time
    23 December 2021
    0 references
    GENETISCHE IMPFSTOFFE HABEN IM VERGLEICH ZU HERKÖMMLICHEN IMPFSTOFFEN MEHRERE POTENZIELLE VORTEILE, EINSCHLIESSLICH GEZIELTER TARGETING, DER VERWENDUNG MEHRERER GENE ZUR VERBESSERUNG DER IMMUNITÄT, DER SYNTHESEGESCHWINDIGKEIT UND DER RISIKOREDUKTION. EVVIVAX Ê EIN NEUES UNTERNEHMEN, DAS (German)
    point in time
    24 December 2021
    0 references
    LAS VACUNAS GENÉTICAS TIENEN MÚLTIPLES BENEFICIOS POTENCIALES, INCLUYENDO LA ORIENTACIÓN ESPECÍFICA, EL USO DE MÚLTIPLES GENES PARA MEJORAR LA INMUNIDAD, LA VELOCIDAD DE SÍNTESIS Y LA REDUCCIÓN DEL RIESGO EN COMPARACIÓN CON LAS VACUNAS CONVENCIONALES. EVVIVAX Ê UNA NUEVA EMPRESA QUE (Spanish)
    point in time
    25 January 2022
    0 references
    GENETISKE VACCINER HAR FLERE POTENTIELLE FORDELE, HERUNDER SPECIFIK MÅLRETNING, ANVENDELSE AF FLERE GENER TIL FORBEDRING AF IMMUNOLOGIEN, RESUMÉERNES HASTIGHED OG RISIKOREDUKTION I FORBINDELSE MED KONVENTIONELLE VACCINER. EVVIVAX Ê EN NY VIRKSOMHED CH (Danish)
    point in time
    5 July 2022
    0 references
    ΤΑ ΓΕΝΕΤΙΚΆ ΕΜΒΌΛΙΑ ΈΧΟΥΝ ΠΟΛΛΑΠΛΆ ΔΥΝΗΤΙΚΆ ΟΦΈΛΗ, ΣΥΜΠΕΡΙΛΑΜΒΑΝΟΜΈΝΗΣ ΤΗΣ ΕΙΔΙΚΉΣ ΣΤΌΧΕΥΣΗΣ, ΤΗΣ ΧΡΉΣΗΣ ΠΟΛΛΑΠΛΏΝ ΓΟΝΙΔΊΩΝ ΓΙΑ ΤΗ ΒΕΛΤΊΩΣΗ ΤΗΣ ΑΝΟΣΟΛΟΓΊΑΣ, ΤΗΣ ΤΑΧΎΤΗΤΑΣ ΤΩΝ ΠΕΡΙΛΉΨΕΩΝ ΚΑΙ ΤΗΣ ΜΕΊΩΣΗΣ ΤΟΥ ΚΙΝΔΎΝΟΥ ΣΕ ΣΧΈΣΗ ΜΕ ΤΑ ΣΥΜΒΑΤΙΚΆ ΕΜΒΌΛΙΑ. EVVIVAX Å ΜΙΑ ΝΈΑ ΕΤΑΙΡΕΊΑ CH (Greek)
    point in time
    5 July 2022
    0 references
    GENETSKA CJEPIVA IMAJU VIŠESTRUKE POTENCIJALNE KORISTI, UKLJUČUJUĆI CILJANO USMJERAVANJE, UPOTREBU VIŠESTRUKIH GENA ZA POBOLJŠANJE IMUNOLOGIJE, BRZINU SAŽETAKA I SMANJENJE RIZIKA U ODNOSU NA KONVENCIONALNA CJEPIVA. EVVIVAX Ê NOVA TVRTKA CH (Croatian)
    point in time
    5 July 2022
    0 references
    VACCINURILE GENETICE AU MULTIPLE BENEFICII POTENȚIALE, INCLUSIV DIRECȚIONAREA SPECIFICĂ, UTILIZAREA GENELOR MULTIPLE PENTRU ÎMBUNĂTĂȚIREA IMUNOLOGIEI, VITEZA REZUMATELOR ȘI REDUCEREA RISCURILOR LEGATE DE VACCINURILE CONVENȚIONALE. EVVIVAX ĂŠ O NOUĂ COMPANIE CH (Romanian)
    point in time
    5 July 2022
    0 references
    GENETICKÉ VAKCÍNY MAJÚ MNOHONÁSOBNÉ POTENCIÁLNE PRÍNOSY VRÁTANE ŠPECIFICKÉHO ZACIELENIA, POUŽÍVANIA VIACERÝCH GÉNOV NA ZLEPŠENIE IMUNOLÓGIE, RÝCHLOSTI ZHRNUTÍ A ZNÍŽENIA RIZIKA V SÚVISLOSTI S KONVENČNÝMI VAKCÍNAMI. EVVIVAX Ê A NOVÁ SPOLOČNOSŤ CH (Slovak)
    point in time
    5 July 2022
    0 references
    IL-VAĊĊINI ĠENETIĊI GĦANDHOM DIVERSI BENEFIĊĊJI POTENZJALI, INKLUŻ L-IMMIRAR SPEĊIFIKU, L-UŻU TA’ ĠENI MULTIPLI BIEX ITEJBU L-IMMUNOLOĠIJA, IL-VELOĊITÀ TAS-SOMMARJI U T-TNAQQIS TAR-RISKJU FIR-RIGWARD TAL-VAĊĊINI KONVENZJONALI. EVVIVAX Ê KUMPANIJA ĠDIDA CH (Maltese)
    point in time
    5 July 2022
    0 references
    As vacinas genéticas têm múltiplas vantagens potenciais, incluindo uma orientação específica, a utilização de múltiplos genes para melhorar a imunologia, a velocidade dos resumos e a redução do risco em relação às vacinas convencionais. EVVIVAX Ê Uma NOVA EMPRESA CH (Portuguese)
    point in time
    5 July 2022
    0 references
    GENEETTISILLÄ ROKOTTEILLA ON USEITA MAHDOLLISIA HYÖTYJÄ, KUTEN ERITYINEN KOHDENTAMINEN, USEIDEN GEENIEN KÄYTTÖ IMMUNOLOGIAN PARANTAMISEKSI, YHTEENVETOJEN NOPEUS JA TAVANOMAISIIN ROKOTTEISIIN LIITTYVÄN RISKIN VÄHENTÄMINEN. EVVIVAX Ê UUSI YRITYS CH (Finnish)
    point in time
    5 July 2022
    0 references
    SZCZEPIONKI GENETYCZNE MAJĄ WIELE POTENCJALNYCH KORZYŚCI, W TYM KONKRETNE UKIERUNKOWANIE, WYKORZYSTANIE WIELU GENÓW W CELU POPRAWY IMMUNOLOGII, SZYBKOŚĆ STRESZCZENIA I ZMNIEJSZENIE RYZYKA W ODNIESIENIU DO KONWENCJONALNYCH SZCZEPIONEK. EVVIVAX Ê NOWA FIRMA CH (Polish)
    point in time
    5 July 2022
    0 references
    GENETSKA CEPIVA IMAJO ŠTEVILNE POTENCIALNE KORISTI, VKLJUČNO S POSEBNIM USMERJANJEM, UPORABO VEČ GENOV ZA IZBOLJŠANJE IMUNOLOGIJE, HITROSTJO POVZETKOV IN ZMANJŠANJEM TVEGANJA V ZVEZI S KONVENCIONALNIMI CEPIVI. EVVIVAX Ê NOVO PODJETJE CH (Slovenian)
    point in time
    5 July 2022
    0 references
    GENETICKÉ VAKCÍNY MAJÍ ŘADU POTENCIÁLNÍCH PŘÍNOSŮ, VČETNĚ SPECIFICKÉHO CÍLENÍ, POUŽÍVÁNÍ VÍCE GENŮ KE ZLEPŠENÍ IMUNOLOGIE, RYCHLOSTI SOUHRNŮ A SNÍŽENÍ RIZIKA VE VZTAHU K KONVENČNÍM OČKOVACÍM LÁTKÁM. EVVIVAX Ê A NEW COMPANY CH (Czech)
    point in time
    5 July 2022
    0 references
    GENETINĖS VAKCINOS TURI DAUGIALYPĘ POTENCIALIĄ NAUDĄ, ĮSKAITANT SPECIFINĮ TIKSLINIMĄ, DAUGELIO GENŲ NAUDOJIMĄ IMUNOLOGIJAI GERINTI, SANTRAUKŲ GREITĮ IR RIZIKOS, SUSIJUSIOS SU ĮPRASTINĖMIS VAKCINOMIS, MAŽINIMĄ. EVVIVAX Ê NAUJA ĮMONĖ (Lithuanian)
    point in time
    5 July 2022
    0 references
    ĢENĒTISKĀM VAKCĪNĀM IR VAIRĀKI POTENCIĀLI IEGUVUMI, TOSTARP ĪPAŠA MĒRĶORIENTĀCIJA, VAIRĀKU GĒNU IZMANTOŠANA IMUNOLOĢIJAS UZLABOŠANAI, KOPSAVILKUMU ĀTRUMS UN RISKA SAMAZINĀŠANA SAISTĪBĀ AR TRADICIONĀLAJĀM VAKCĪNĀM. EVVIVAX IR JAUNS UZŅĒMUMS CH (Latvian)
    point in time
    5 July 2022
    0 references
    ГЕНЕТИЧНИТЕ ВАКСИНИ ИМАТ МНОЖЕСТВО ПОТЕНЦИАЛНИ ПОЛЗИ, ВКЛЮЧИТЕЛНО СПЕЦИФИЧНО НАСОЧВАНЕ, ИЗПОЛЗВАНЕТО НА МНОЖЕСТВО ГЕНИ ЗА ПОДОБРЯВАНЕ НА ИМУНОЛОГИЯТА, СКОРОСТТА НА РЕЗЮМЕТАТА И НАМАЛЯВАНЕТО НА РИСКА ВЪВ ВРЪЗКА С КОНВЕНЦИОНАЛНИТЕ ВАКСИНИ. EVVIVAX Ê НОВА КОМПАНИЯ (Bulgarian)
    point in time
    5 July 2022
    0 references
    A GENETIKAI VAKCINÁK SZÁMOS LEHETSÉGES ELŐNNYEL JÁRNAK, BELEÉRTVE A CÉLZOTT CÉLZOTTSÁGOT, AZ IMMUNOLÓGIA JAVÍTÁSÁRA TÖBB GÉN ALKALMAZÁSÁT, AZ ÖSSZEFOGLALÓK SEBESSÉGÉT ÉS A HAGYOMÁNYOS VAKCINÁKKAL KAPCSOLATOS KOCKÁZATOK CSÖKKENTÉSÉT. EVVIVAX Ê EGY ÚJ CÉG CH (Hungarian)
    point in time
    5 July 2022
    0 references
    IS IOMAÍ BUNTÁISTE A D’FHÉADFADH A BHEITH AG VACSAÍNÍ GÉINITEACHA, LENA N-ÁIRÍTEAR SPRIOCDHÍRIÚ SONRACH, ILGHÉINTE A ÚSÁID CHUN IMDHÍONEOLAÍOCHT A FHEABHSÚ, LUAS NA N-ACHOIMRÍ AGUS LAGHDÚ AN RIOSCA I NDÁIL LE GNÁTHVACSAÍNÍ. EVVIVAX Ê CUIDEACHTA NUA CH (Irish)
    point in time
    5 July 2022
    0 references
    GENETISKA VACCINER HAR FLERA POTENTIELLA FÖRDELAR, INKLUSIVE SPECIFIK INRIKTNING, ANVÄNDNING AV FLERA GENER FÖR ATT FÖRBÄTTRA IMMUNOLOGIN, HASTIGHETEN PÅ SAMMANFATTNINGARNA OCH MINSKNINGEN AV RISKEN I FÖRHÅLLANDE TILL KONVENTIONELLA VACCINER. EVVIVAX ÅŠ ETT NYTT FÖRETAG CH (Swedish)
    point in time
    5 July 2022
    0 references
    GENEETILISTEL VAKTSIINIDEL ON MITMEID VÕIMALIKKE EELISEID, SEALHULGAS SIHTIMINE, MITME GEENI KASUTAMINE IMMUNOLOOGIA PARANDAMISEKS, KOKKUVÕTETE TEGEMISE KIIRUS JA RISKI VÄHENDAMINE VÕRRELDES TAVAPÄRASTE VAKTSIINIDEGA. EVVIVAX Ê UUS FIRMA CH (Estonian)
    point in time
    5 July 2022
    0 references
    location (string)
    ROMA
    0 references
    date of last update
    8 April 2023
    0 references

    Identifiers

    Italian Unique Project Code
    F89J18000160007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035463&oldid=42380214"